




Non-Alcoholic Fatty Liver Disease and Sepsis
Nealkoholna masna bolest jetre i sepsa
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 Sepsis and non-alcoholic fatty liver disease (NAFLD) are both inflam-
mation-related entities and major disease burdens with high impact on 
modern healthcare systems. Sepsis is a heterogeneous syndrome, with an 
outcome dependent on the culprit pathogen, infection site and host factors 
(e.g. comorbidities, genetic factors, immunosuppression, including the de-
gree and types of the host immune response). Only recently has the role of 
liver in sepsis begun to be revealed. Evidence has shown that liver dysfunc-
tion in sepsis in patients without pre-existing liver disease is an independent 
predictor of mortality (54-68%), higher than the mortality rates of sepsis 
complicated with respiratory or kidney failure[1]. On the other hand, chronic 
liver disease is a risk factor for the progression of infection to sepsis. The 
patients with liver cirrhosis are exposed to an increased risk of developing 
bacterial infections, have ten times more common bloodstream infections 
with a fourfold increase in mortality in comparison to patients without cir-
rhosis. Progression to septic shock in these patients is associated with an 
in-hospital mortality rate as high as 70%[2]. These clinical findings highlight 
the critical role of liver as an immunomodulatory organ in sepsis.
 Non-alcoholic fatty liver disease (NAFLD) is the most common cause of 
liver disease[3, 4]. Although the pathogenesis of NAFLD is linked with sys-
temic changes in immune response, the question remains whether patients 
with NAFLD are more prone to bacterial infections and what is the impact of 
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persistent local inflammation to the systemic response 
to infection, sepsis course and outcome.
 There are only several clinical studies that exam-
ined the role of NAFLD in infectious diseases: (1) it 
was shown that the post-transplant risk for infection 
is significantly higher in patients transplanted due to 
non-alcoholic steatohepatitis (NASH) when compared 
to other transplant indications[5]; (2) in patients suffer-
ing from advanced liver disease, the presence of stea-
tosis measured by the controlled attenuation parame-
ter (CAP) ≥220 dB/m is associated with an increased 
risk of decompensation and bacterial infection[6]; (3) 
NAFLD was associated with an increase in all-cause 
mortality in patients with community acquired pneu-
monia even in the absence of advanced fibrosis[7]; (4) 
bacteraemia of gastrointestinal origin was more com-
mon in patients with NAFLD[8]. More recently, NAFLD 
was identified as a risk factor for Clostridioides difficile 
infection[9].
 In this issue of the Croatian Journal of Infection, 
Gjurašin et al.[10] have shown that invasive Group B 
Streptococcus (GBS) disease in patients with NAFLD 
is associated with higher mortality than in patients 
without NAFLD. Moreover, this appears to be inde-
pendent of other components of metabolic syndrome, 
such as obesity and diabetes mellitus. Furthermore, 
the authors have found that nosocomial infections and 
acute renal failure are more common in the NAFLD 
group. This highlights the need for further prospective 
studies to evaluate the association of NAFLD with the 
outcomes of bacterial infections.
 The study is a part of the ongoing Installation Re-
search Project „The role of immune semaphorins in 
NAFLD and sepsis”, SepsisFAT, financed by the Cro-
atian Science Foundation[11]. The researchers plan to 
conduct the first comprehensive interdisciplinary clin-
ical, microbiological, immunological and biomarker 
study of the impact of NAFLD on sepsis.
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 The impact of NAFLD on severe bacterial infec-
tions, sepsis and pneumonia has not been established 
so far. Although there is an abundance of data on the 
gut-liver axis and changes in gut microbiome shown to 
be associated with NAFLD and progression to NASH, 
there are no data on the incidence, clinical course and 
outcome of gastrointestinal infections in this popula-
tion, specifically the risk for Clostridiodes difficile in-
fection. In addition, there is a question if NAFLD gut 
microbiome profile contributes to the colonization 
with MDR bacteria. Therefore, significant gaps in our 
understanding of the role of NAFLD in infectious dis-
eases exist, and „SepsisFAT” might provide the insight 
into these clinical questions. Importantly, the profile of 
pro-inflammatory and anti-inflammatory mediators 
in the presence of NAFLD to bacterial infections will 
be described. There are critical gaps in our knowledge 
of biomarkers of sepsis severity, treatment response 
and prognosis in this group. This integrated approach 
could identify new diagnostic and prognostic bio-
markers and new targets for prevention and more 
promising treatment options.
REFERENCES
 [1] Yan J, Li S, Li S. The role of the liver in sepsis. Int Rev Immunol. 
2014;33(6):498-510.
 [2] Wong F, Bernardi M, Balk R, Christman B, Moreau R, Gar-
cia-Tsao G, i sur. Sepsis in cirrhosis: report on the 7th meeting 
of the International Ascites Club. Gut. 2005;54(5):718-25.
